The development of a next generation NK cell engager platform by integrating a potency-reduced IL-15 variant to enhance antitumor activity

By integrating IL15v into our anti-NKp46 based NKCEs, IL15v-NKCE has exhibited enhanced anti-tumor efficacy while maintaining an acceptable safety profile, thereby positioning it as a promising next-generation therapeutic modality for NK cell-based therapy.